Almost a year after a 22-year-old man was fatally shot in Raleigh, police have arrested a second man in his death, officials announced Monday. Emmanuel Ajene Jones, 22, of Durham, is charged with ...

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

MORRISVILLE, N.C. (WNCN) – It was another record-breaking month for travel at Raleigh-Durham International Airport. Nearly 1.4 million passengers traveled through the airport in October, which marks ...

Tis the season! You don't want to miss the pageantry, fun and excitement of the 2024 ABC11 Crossroads Ford Raleigh Christmas Parade presented by Shop Local Raleigh and sponsored by Crossroad Ford ...

DURHAM, N.C. (WTVD) -- The Durham County Sheriff's Office said Friday that it assisted US Homeland Security in an investigation that led to an arrest of a woman suspected of cocaine trafficking.

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock opportunity. I think the global biopharma company has been dripping with promise ...

Freelance writer Amanda C. Kooser covers gadgets and tech news with a twist for CNET. When not wallowing in weird gear and iPad apps for cats, she can be found tinkering with her 1956 DeSoto.

The GSK share price has tumbled recently on a number of factors, but I think its fundamentals look strong, leaving the stock undervalued right now. When investing, your capital is at risk.

GSK’s (LSE: GSK) share price is down 28% from its 15 May 12-month traded high of £18.19. As a shareholder, this raises the question of whether I should sell, keep what I have, or buy more. In my ...

‘Tis the season to be dazzled! As the air turns crisp and the holiday spirit fills the air, Raleigh and its neighboring areas and counties transform into a magical wonderland of twinkling lights and ...

Two years ago, Toronto-listed legal and information services player Dye & Durham’s chief executive Matthew Proud was running rings around takeover target Link Administration Holdings.

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...